Chemotherapy without acute leukemia as secondary diagnosis without cc/mcc DRG 848

by

The 2024 Diagnosis Related Groups dataset

DRG 848

Chemotherapy without acute leukemia as secondary diagnosis without cc/mcc

Z08  Encounter for follow-up examination after completed treatment for malignant neoplasm

  • Z08 is a billable/specific ICD-10-CM code that can be used to indicate a diagnosis for reimbursement purposes.
  • Short description: Encntr for follow-up exam after trtmt for malignant neoplasm
  • The 2024 edition of ICD-10-CM Z08 became effective on October 1, 2023.
  • This is the American ICD-10-CM version of Z08 – other international versions of ICD-10 Z08 may differ.

Applicable To

  • Medical surveillance following completed treatment

Use Additional

  • code to identify any acquired absence of organs (Z90.-)

Type 1 Excludes

  • aftercare following medical care (Z43–Z49, Z51)

The following code(s) above Z08 contain annotation back-references

 that may be applicable to Z08:

  • Z00-Z99  Factors influencing health status and contact with health services
  • Z00-Z13  Persons encountering health services for examinations

Approximate Synonyms

  • Follow up exam after cancer treatment completion
  • Follow up exam after completion of cancer treatment done
  • Vaginal pap, had hysterectomy for cancer
  • Vaginal papanicolaou smear with history of hysterectomy for cancer done

Present On Admission

  • Z08 is considered exempt from POA reporting.

ICD-10-CM Z08 is grouped within Diagnostic Related Group(s) (MS-DRG v41.0):

  • 826 Myeloproliferative disorders or poorly differentiated neoplasms with major o.r. Procedures with mcc
  • 827 Myeloproliferative disorders or poorly differentiated neoplasms with major o.r. Procedures with cc
  • 828 Myeloproliferative disorders or poorly differentiated neoplasms with major o.r. Procedures without cc/mcc
  • 829 Myeloproliferative disorders or poorly differentiated neoplasms with other procedures with cc/mcc
  • 830 Myeloproliferative disorders or poorly differentiated neoplasms with other procedures without cc/mcc
  • 837 Chemotherapy with acute leukemia as secondary diagnosis or with high dose chemotherapy agent with mcc
  • 838 Chemotherapy with acute leukemia as secondary diagnosis with cc or high dose chemotherapy agent
  • 839 Chemotherapy with acute leukemia as secondary diagnosis without cc/mcc
  • 846 Chemotherapy without acute leukemia as secondary diagnosis with mcc
  • 847 Chemotherapy without acute leukemia as secondary diagnosis with cc
  • 848 Chemotherapy without acute leukemia as secondary diagnosis without cc/mcc

Convert Z08 to ICD-9-CMCode History

  • 2016 (effective 10/1/2015): New code (first year of non-draft ICD-10-CM)
  • 2017 (effective 10/1/2016): No change
  • 2018 (effective 10/1/2017): No change
  • 2019 (effective 10/1/2018): No change
  • 2020 (effective 10/1/2019): No change
  • 2021 (effective 10/1/2020): No change
  • 2022 (effective 10/1/2021): No change
  • 2023 (effective 10/1/2022): No change
  • 2024 (effective 10/1/2023): No change

Code annotations containing back-references to Z08:

Diagnosis Index entries containing back-references to Z08:

Z51.11  Encounter for antineoplastic chemotherapy

  • Z51.11 is a billable/specific ICD-10-CM code that can be used to indicate a diagnosis for reimbursement purposes.
  • The 2024 edition of ICD-10-CM Z51.11 became effective on October 1, 2023.
  • This is the American ICD-10-CM version of Z51.11 – other international versions of ICD-10 Z51.11 may differ.

The following code(s) above Z51.11 contain annotation back-references

 that may be applicable to Z51.11:

  • Z00-Z99  Factors influencing health status and contact with health services
  • Z40-Z53  Encounters for other specific health care
  • Z51  Encounter for other aftercare and medical care
  • Z51.1  Encounter for antineoplastic chemotherapy and immunotherapy

Approximate Synonyms

  • Cancer chemotherapy
  • Chemotherapy
  • Chemotherapy done
  • Chemotherapy for neoplasm done

Present On Admission

  • Z51.11 is considered exempt from POA reporting.

ICD-10-CM Z51.11 is grouped within Diagnostic Related Group(s) (MS-DRG v41.0):

  • 826 Myeloproliferative disorders or poorly differentiated neoplasms with major o.r. Procedures with mcc
  • 827 Myeloproliferative disorders or poorly differentiated neoplasms with major o.r. Procedures with cc
  • 828 Myeloproliferative disorders or poorly differentiated neoplasms with major o.r. Procedures without cc/mcc
  • 829 Myeloproliferative disorders or poorly differentiated neoplasms with other procedures with cc/mcc
  • 830 Myeloproliferative disorders or poorly differentiated neoplasms with other procedures without cc/mcc
  • 837 Chemotherapy with acute leukemia as secondary diagnosis or with high dose chemotherapy agent with mcc
  • 838 Chemotherapy with acute leukemia as secondary diagnosis with cc or high dose chemotherapy agent
  • 839 Chemotherapy with acute leukemia as secondary diagnosis without cc/mcc
  • 846 Chemotherapy without acute leukemia as secondary diagnosis with mcc
  • 847 Chemotherapy without acute leukemia as secondary diagnosis with cc
  • 848 Chemotherapy without acute leukemia as secondary diagnosis without cc/mcc

Convert Z51.11 to ICD-9-CMCode History

  • 2016 (effective 10/1/2015): New code (first year of non-draft ICD-10-CM)
  • 2017 (effective 10/1/2016): No change
  • 2018 (effective 10/1/2017): No change
  • 2019 (effective 10/1/2018): No change
  • 2020 (effective 10/1/2019): No change
  • 2021 (effective 10/1/2020): No change
  • 2022 (effective 10/1/2021): No change
  • 2023 (effective 10/1/2022): No change
  • 2024 (effective 10/1/2023): No change

Diagnosis Index entries containing back-references to Z51.11:

  • Chemotherapy (session) (for)
    • cancer Z51.11
    • neoplasm Z51.11
  • Encounter (with health service) (for) Z76.89
    • chemotherapy for neoplasm Z51.11
  • Maintenance (encounter for)
    • antineoplastic chemotherapy Z51.11

Z51.12  Encounter for antineoplastic immunotherapy

  • Z51.12 is a billable/specific ICD-10-CM code that can be used to indicate a diagnosis for reimbursement purposes.
  • The 2024 edition of ICD-10-CM Z51.12 became effective on October 1, 2023.
  • This is the American ICD-10-CM version of Z51.12 – other international versions of ICD-10 Z51.12 may differ.

The following code(s) above Z51.12 contain annotation back-references

 that may be applicable to Z51.12:

  • Z00-Z99  Factors influencing health status and contact with health services
  • Z40-Z53  Encounters for other specific health care
  • Z51  Encounter for other aftercare and medical care
  • Z51.1  Encounter for antineoplastic chemotherapy and immunotherapy

Present On Admission

  • Z51.12 is considered exempt from POA reporting.

ICD-10-CM Z51.12 is grouped within Diagnostic Related Group(s) (MS-DRG v41.0):

  • 826 Myeloproliferative disorders or poorly differentiated neoplasms with major o.r. Procedures with mcc
  • 827 Myeloproliferative disorders or poorly differentiated neoplasms with major o.r. Procedures with cc
  • 828 Myeloproliferative disorders or poorly differentiated neoplasms with major o.r. Procedures without cc/mcc
  • 829 Myeloproliferative disorders or poorly differentiated neoplasms with other procedures with cc/mcc
  • 830 Myeloproliferative disorders or poorly differentiated neoplasms with other procedures without cc/mcc
  • 837 Chemotherapy with acute leukemia as secondary diagnosis or with high dose chemotherapy agent with mcc
  • 838 Chemotherapy with acute leukemia as secondary diagnosis with cc or high dose chemotherapy agent
  • 839 Chemotherapy with acute leukemia as secondary diagnosis without cc/mcc
  • 846 Chemotherapy without acute leukemia as secondary diagnosis with mcc
  • 847 Chemotherapy without acute leukemia as secondary diagnosis with cc
  • 848 Chemotherapy without acute leukemia as secondary diagnosis without cc/mcc

Convert Z51.12 to ICD-9-CMCode History

  • 2016 (effective 10/1/2015): New code (first year of non-draft ICD-10-CM)
  • 2017 (effective 10/1/2016): No change
  • 2018 (effective 10/1/2017): No change
  • 2019 (effective 10/1/2018): No change
  • 2020 (effective 10/1/2019): No change
  • 2021 (effective 10/1/2020): No change
  • 2022 (effective 10/1/2021): No change
  • 2023 (effective 10/1/2022): No change
  • 2024 (effective 10/1/2023): No change

Diagnosis Index entries containing back-references to Z51.12:

Leave a Comment